Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug;40(8):1919-1925.
doi: 10.1111/jgh.17015. Epub 2025 May 23.

Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study

Leith Ghani  1 , Majd B Aboona  1 , Claire S Faulkner  2 , Pooja Rangan  3 , Moises Nevah Rubin  4 , Ma Ai Thanda Han  5   4 , Michael B Fallon  5   4 , Vincent L Chen  6 , Karn Wijarnpreecha  5   4   7
Affiliations
Multicenter Study

Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study

Leith Ghani et al. J Gastroenterol Hepatol. 2025 Aug.

Abstract

Background and aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Since the adoption of the new terminology from the Delphi Consensus statement, there has not been a large multicenter cohort study of MASLD among lean versus non-lean individuals. This study aims to assess prevalence and incidence outcomes among lean and non-lean individuals with MASLD in a diverse patient cohort.

Methods: We conducted a retrospective multicenter study on patients with MASLD at the Banner and the University of Michigan Health systems from 2012 to 2023. Main outcomes included mortality and incidence of cirrhosis, cardiovascular disease (CVD), major adverse liver outcome (MALO), and cancer.

Results: Seventy-five thousand nine hundred twenty-one patients were included in this cohort with 5% lean individuals. In this cohort, 4.99% were lean, 23.16% were overweight, 28.47% were obesity class I, and 43.39% were obesity class II-III; 58.49% were female; and 66.32% were non-Hispanic White, 22.23% Hispanic, 4.75% Black, 1.71% Native Americans (NAs), and 1.97% Asian/Pacific Islander. After adjusting for confounders, lean individuals had a higher mortality, higher incidence of CVD, and higher incidence of MALO.

Conclusions: Lean individuals have a higher mortality, higher cardiovascular burden, and higher incidence of MALO compared to non-lean individuals. Further studies are warranted to explore lean patients with MASLD, and interventions are needed to decrease mortality in this patient population.

Keywords: Hispanic paradox; MASLD; Native American; lean individuals; major adverse liver outcomes; mortality.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Statement: VLC received research funding from AstraZeneca and KOWA (to University of Michigan).

References

    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79: 1542–56. - PubMed
    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77: 1335–47. - PMC - PubMed
    1. Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022; 28: 841–50. - PMC - PubMed
    1. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32: 197–213. - PMC - PubMed
    1. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5: 739–52. - PubMed

Publication types

LinkOut - more resources